Measurement of Elecsys NT-proBNP in serum, K2 EDTA and heparin plasma.

G. Lippi,G. Salvagno,M. Montagnana,G. Guidi

DOI: https://doi.org/10.1016/J.CLINBIOCHEM.2007.02.002

IF: 3.625

2007-06-01

Clinical Biochemistry

Abstract:

What problem does this paper attempt to address?

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Yuan Kong,Yi-Lin Wu,Yang Song,Min-Min Shi,Xie-Na Cao,Hong-Yan Zhao,Ya-Zhen Qin,Yue-Yun Lai,Hao Jiang,Qian Jiang,Xiao-Jun Huang

DOI: https://doi.org/10.1186/s12967-017-1286-5

IF: 8.44

2017-01-01

Journal of Translational Medicine

Abstract:BACKGROUND:As one of the major treatment obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), relapse of Ph+ALL may result from the persistence of leukemia-propagating cells (LPCs). Research using a xenograft mouse assay recently determined that LPCs were enriched in the CD34+CD38-CD58- fraction in human Ph+ALL. Additionally, a cohort study demonstrated that Ph+ALL patients with a LPCs phenotype at diagnosis exhibited a significantly higher cumulative incidence of relapse than those with the other cell phenotypes even with uniform front-line imatinib-based therapy pre- and post-allotransplant, thus highlighting the need for novel LPCs-based therapeutic strategies.METHODS:RNA sequencing (RNA-Seq) and real-time quantitative polymerase chain reaction (qRT-PCR) were performed to analyze the gene expression profiles of the sorted LPCs and other cell fractions from patients with de novo Ph+ALL. In order to assess the effects of the selective BCR-ABL and/or Janus kinase (JAK)2 inhibition therapy by the treatment with single agents or a combination of ruxolitinib and imatinib or nilotinib on Ph+ALL LPCs, drug-induced apoptosis of LPCs was investigated in vitro, as well as in vivo using sublethally irradiated and anti-CD122-conditioned NOD/SCID xenograft mouse assay. Moreover, western blot analyses were performed on the bone marrow cells harvested from the different groups of recipient mice.RESULTS:RNA-Seq and qRT-PCR demonstrated that JAK2 was more highly expressed in the sorted LPCs than in the other cell fractions in de novo Ph+ALL patients. Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level.CONCLUSIONS:In summary, this pre-clinical study provides a scientific rationale for simultaneously targeting BCR-ABL and JAK2 activities as a promising anti-LPCs therapeutic approach for patients with de novo Ph+ALL.
Targeting KDM4 for treating PAX3-FOXO1–driven alveolar rhabdomyosarcoma

Shivendra Singh,Ahmed Abu-Zaid,Hongjian Jin,Jie Fang,Qiong Wu,Tingting Wang,Helin Feng,Waise Quarni,Ying Shao,Lily Maxham,Alireza Abdolvahabi,Mi-Kyung Yun,Sivaraja Vaithiyalingam,Haiyan Tan,John Bowling,Victoria Honnell,Brandon Young,Yian Guo,Richa Bajpai,Mark Hatley,Beisi Xu,Yiping Fan,Gang Wu,Taosheng Chen,Zoran Rankovic,Yimei Li,John Easton,Junmin Peng,Xiang Chen,Ruoning Wang,Jun Yang,Shondra M. Pruett-Miller,Gerard C. Grosveld,Eleanor Y. Chen,Peter W. Lewis,Andrew J. Murphy,Stephen W. White,Andrew M. Davidoff

DOI: https://doi.org/10.1126/scitranslmed.abq2096

IF: 17.1

2022-07-14

Science Translational Medicine

Abstract:Chimeric transcription factors drive lineage-specific oncogenesis but are notoriously difficult to target. Alveolar rhabdomyosarcoma (RMS) is an aggressive childhood soft tissue sarcoma transformed by the pathognomonic Paired Box 3–Forkhead Box O1 (PAX3-FOXO1) fusion protein, which governs a core regulatory circuitry transcription factor network. Here, we show that the histone lysine demethylase 4B (KDM4B) is a therapeutic vulnerability for PAX3-FOXO1 + RMS. Genetic and pharmacologic inhibition of KDM4B substantially delayed tumor growth. Suppression of KDM4 proteins inhibited the expression of core oncogenic transcription factors and caused epigenetic alterations of PAX3-FOXO1–governed superenhancers. Combining KDM4 inhibition with cytotoxic chemotherapy led to tumor regression in preclinical PAX3-FOXO1 + RMS subcutaneous xenograft models. In summary, we identified a targetable mechanism required for maintenance of the PAX3-FOXO1–related transcription factor network, which may translate to a therapeutic approach for fusion-positive RMS.

cell biology,medicine, research & experimental
Abstract 4738: Overcoming therapy resistance in rhabdomyosarcoma by targeting the PI3K-MAPK pathway

Yadong Wang,Eleanor Chen

DOI: https://doi.org/10.1158/1538-7445.am2024-4738

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Rhabdomyosarcoma (RMS) is a devastating pediatric cancer. There has not been any significant change in the treatment options for the last 4 decades, especially for relapsed or advanced disease. There is an urgent need to identify alternative treatment options to improve survival outcomes of RMS patients. RMS is comprised of two major subtypes as defined by the presence or absence of PAX3/PAX7-FOXO1 gene fusion. Fusion-negative RMS (FN RMS) is characterized by alterations in the RAS-PI3K-MAPK pathway in >90% of the cases. However, the role of the PI3K-MAPK pathway in therapy resistance and disease relapse remains poorly characterized. We have generated two FN-RMS lines, RD and SMS-CTR, with resistance to the standard-of-care chemotherapeutic agent, vincristine, through long-term culturing in incrementally increased concentrations of the drug. By RNA sequencing, vincristine-resistant RD and SMS-CTR cells demonstrated increased expression of genes in the RAS-PI3K-MAPK pathway compared to the parental lines. We hypothesize that increased activity of the PI3K-MAPK pathway contributes to therapy resistance in FN RMS. To test the hypothesis, we first showed that targeted disruption of PIK3CA by shRNA inhibited the cell growth of vincristine-resistant FN RMS cells. The same cells also showed increased sensitivity to the MEK inhibitor, trametinib, as well as the PIK3Cα inhibitor, alpelisib, compared to the parental cells. We then showed that zebrafish FN-RMS tumors treated with the combination of vincristine and alpelisib significantly inhibited tumor growth compared to the treatment with each agent alone. Through integrative analysis of RNA sequencing and ATAC-seq data, we identified MYOD1 and NFATC2 as among the top candidate upstream regulators. Targeted disruption of either MYOD1 or NFATC2 by CRISPR/Cas9 reduced cell growth of vincristine-resistant FN RMS cells and altered expression of the genes in the PI3K-MAPK pathway, implicating MYOD1 and NFATC2 in driving abnormal activity of this pathway. To assess the relevance of our findings in the clinical settings, we showed that selective components in the PI3K-MAPK pathways are up-regulated in 3 matched primary-recurrence/metastasis paraffinized tissue samples of human FN RMS by the NanoString GeoMx Digital Spatial Profiler (DSP) platform. Our findings indicate that targeting the PI3K-MAPK pathway is a promising targeted therapy option for overcoming therapy resistance in RMS. Citation Format: Yadong Wang, Eleanor Chen. Overcoming therapy resistance in rhabdomyosarcoma by targeting the PI3K-MAPK pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4738.

oncology
Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma

Joseph Hsieh,Etienne P. Danis,Charles R. Owens,Janet K. Parrish,Nathan L. Nowling,Arthur R. Wolin,Stephen Connor Purdy,Sheera R. Rosenbaum,Atma M. Ivancevic,Edward B. Chuong,Heide L. Ford,Paul Jedlicka

DOI: https://doi.org/10.1038/s41388-024-03201-2

IF: 8.756

2024-10-26

Oncogene

Abstract:Rhabdomyosarcoma (RMS), a malignancy of impaired myogenic differentiation, is the most common soft tissue pediatric cancer. PAX3-FOXO1 oncofusions drive the majority of the clinically more aggressive fusion-positive rhabdomyosarcoma (FP-RMS). Recent studies have established an epigenetic basis for PAX3-FOXO1-driven oncogenic processes. However, details of PAX3-FOXO1 epigenetic mechanisms, including interactions with, and dependence on, other chromatin and transcription factors, are incompletely understood. We previously identified a novel disease-promoting epigenetic axis in RMS, involving the histone demethylase KDM3A and the ETS1 transcription factor, and demonstrated that this epigenetic axis interfaces with PAX3-FOXO1 both phenotypically and transcriptomically, including co-regulation of biological processes and genes important to FP-RMS progression. In this study, we demonstrate that KDM3A and ETS1 colocalize with PAX3-FOXO1 to enhancers of important disease-promoting genes in FP-RMS, including FGF8, IL4R, and MEST, as well as PODXL, which we define herein as a new FP-RMS-promoting gene. We show that ETS1, which is induced by both PAX3-FOXO1 and KDM3A, exists in complex with PAX3-FOXO1, and augments PAX3-FOXO1 chromatin occupancy. We further show that the PAX3-FOXO1/ETS1 complex can be disrupted by the clinically relevant small molecule inhibitor YK-4-279. YK-4-279 displaces PAX3-FOXO1 from chromatin and interferes with PAX3-FOXO1-dependent gene regulation, resulting in potent inhibition of growth and invasive properties in FP-RMS, along with downregulation of FGF8, IL4R, MEST and PODXL expression. We additionally show that, in some FP-RMS, KDM3A also increases PAX3-FOXO1 levels. Together, our studies illuminate mechanisms of action of the KDM3A/ETS1 regulatory module, and reveal novel targetable mechanisms of PAX3-FOXO1 chromatin complex regulation, in FP-RMS.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Abstract 1093: Small molecule inhibitors of the PAX3::FOXO1 fusion protein in rhabdomyosarcoma

Taryn Shaw,Kay Nakazawa,Purushottam Tiwari,Eryn Nelson,Jeffrey Formen,Christian Wolf,Jeffrey Toretsky,Aykut Üren

DOI: https://doi.org/10.1158/1538-7445.am2024-1093

IF: 11.2

2024-04-04

Cancer Research

Abstract:Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. It is commonly divided into subtypes based on histopathological appearance. The oncogenic fusion proteins PAX3::FOXO1 or PAX7::FOXO1 are present in the alveolar subtype of RMS (ARMS). These chimeric proteins are formed by reciprocal chromosomal translocations and consist of an N-terminal portion of the PAX3 or PAX7 transcription factor fused to a C-terminal portion of the FOXO1 transcription factor. These fusion proteins have been shown to drive malignant transformation in ARMS, and patients with fusion-positive ARMS have a worse prognosis than patients with fusion-negative ARMS and embryonal RMS. We recently reported that piperacetazine, a phenothiazine derivative and first-generation antipsychotic, is capable of binding to and inhibiting the transcriptional activity of PAX3::FOXO1, reducing the expression of PAX3::FOXO1 target genes, and inhibiting the ability of fusion-positive RMS cells to grow in soft agar. We hypothesize that other phenothiazine derivatives may have stronger binding affinity for PAX3::FOXO1 and greater ability to reduce tumor growth in vivo. We employed a structure-activity relationship campaign to develop new phenothiazine derivatives that may be more potent inhibitors of PAX3::FOXO1 than piperacetazine. We synthesized and tested 10 new compounds, in addition to 9 existing FDA-approved phenothiazine derivatives, for their ability to bind to PAX3::FOXO1 and inhibit its transcriptional activity and target gene expression as well as inhibiting the growth of fusion-positive RMS cells in 3D culture. Seven derivatives inhibited PAX3::FOXO1 reporter activity better than piperacetazine, nine of them performed worse, and three of them showed comparable activity to piperacetazine. We demonstrated that piperacetazine does not alter PAX3::FOXO1 levels, subcellular localization, binding to a PAX3::FOXO1 target DNA sequence, or phosphorylation at Ser256 in the FOXO1 portion of the fusion protein. We therefore hypothesize that piperacetazine may be disrupting interactions between PAX3::FOXO1 and its partner proteins. We are employing a proximity-based biotinylation method to identify proteins that are competed away from PAX3::FOXO1 by piperacetazine. Our data suggest that it is possible to target PAX3::FOXO1 protein using small molecules that can directly bind to it and inhibit its activity in fusion-positive RMS cells. Citation Format: Taryn Shaw, Kay Nakazawa, Purushottam Tiwari, Eryn Nelson, Jeffrey Formen, Christian Wolf, Jeffrey Toretsky, Aykut Üren. Small molecule inhibitors of the PAX3::FOXO1 fusion protein in rhabdomyosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1093.

oncology
TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

Gabriel Gallo-Oller,Guillem Pons,Júlia Sansa-Girona,Natalia Navarro,Patricia Zarzosa,Lia García-Gilabert,Paula Cabré-Fernandez,Gabriela Guillén Burrieza,Lorena Valero-Arrese,Miguel F. Segura,José M. Lizcano,José Sánchez de Toledo,Lucas Moreno,Soledad Gallego,Josep Roma

DOI: https://doi.org/10.1186/s40164-024-00503-9

2024-04-07

Experimental Hematology and Oncology

Abstract:Rhabdomyosarcoma (RMS), such as other childhood tumors, has witnessed treatment advancements in recent years. However, high-risk patients continue to face poor survival rates, often attributed to the presence of the PAX3/7-FOXO1 fusion proteins, which has been associated with metastasis and treatment resistance. Despite efforts to directly target these chimeric proteins, clinical success remains elusive. In this study, the main aim was to address this challenge by investigating regulators of FOXO1. Specifically, we focused on TRIB3, a potential regulator of the fusion protein in RMS. Our findings revealed a prominent TRIB3 expression in RMS tumors, highlighting its correlation with the presence of fusion protein. By conducting TRIB3 genetic inhibition experiments, we observed an impairment on cell proliferation. Notably, the knockdown of TRIB3 led to a decrease in PAX3-FOXO1 and its target genes at protein level, accompanied by a reduction in the activity of the Akt signaling pathway. Additionally, inducible silencing of TRIB3 significantly delayed tumor growth and improved overall survival in vivo. Based on our analysis, we propose that TRIB3 holds therapeutic potential for treating the most aggressive subtype of RMS. The findings herein reported contribute to our understanding of the underlying molecular mechanisms driving RMS progression and provide novel insights into the potential use of TRIB3 as a therapeutic intervention for high-risk RMS patients.

oncology,hematology
PAX fusion proteins deregulate gene networks controlling mitochondrial translation in pediatric rhabdomyosarcoma

Bhargab Kalita,Gerard Martinez-Cebrian,Justina McEvoy,Melody Allensworth,Michelle Knight,Alessandro Magli,Rita C R Perlingeiro,Micheal A. Dyer,Elizabeth A. Stewart,Brian David Dynlacht

DOI: https://doi.org/10.1101/2024.07.31.606039

2024-08-03

Abstract:Alveolar rhabdomyosarcoma (ARMS) patients harboring PAX3-FOXO1 and PAX7-FOXO1 fusion proteins exhibit a greater incidence of tumor relapse, metastasis, and poor survival outcome, thereby underscoring the urgent need to develop effective therapies to treat this subtype of childhood cancer. To uncover mechanisms that contribute to tumor initiation, we developed a novel muscle progenitor model and used epigenomic approaches to unravel genome re-wiring events mediated by PAX3/7 fusion proteins. Importantly, these regulatory mechanisms are conserved across established ARMS cell lines, primary tumors, and orthotopic-patient derived xenografts. Among the key targets of PAX3- and PAX7- fusion proteins, we identified a cohort of oncogenes, FGF receptors, and genes essential for mitochondrial metabolism and protein translation, which we successfully targeted in preclinical trials. Our data suggest an explanation for the relative paucity of recurring mutations in this tumor, provide a compelling list of actionable targets, and suggest promising new strategies to treat this tumor.

Cancer Biology
Abstract 1092: RUNX2 inhibition alters PAX3::FOXO1 driven fusion-positive rhabdomyosarcoma cell state and growth

Elizabeth A. Mendes,Audrey L. Chambers,Samantha J. Weitzel,Michael Deel,Aanandi Munshi,Christopher M. Counter,Seth Zimmerman,John Bushweller,Corinne M. Linardic

DOI: https://doi.org/10.1158/1538-7445.am2024-1092

IF: 11.2

2024-03-28

Cancer Research

Abstract:Investigation: Fusion-positive rhabdomyosarcoma (FP-RMS) is an aggressive pediatric cancer of skeletal muscle lineage. While the incidence of RMS is ~4.5 patients per million individuals aged <20 years, 5-year survival for high-risk children is <30%, and <8% when metastatic. The PAX3::FOXO1 (P3F) fusion gene, resulting from t(2:13), is the most prominent fusion oncogene that drives FP-RMS. P3F is a fusion transcription factor and supports FP-RMS by keeping it in a persistent myoblastic state. We found P3F functions in part by suppressing MST kinase activity in the Hippo tumor suppressor pathway, a developmental pathway involved in cell fate and organ size. To investigate how this may rewire gene expression to support FP-RMS, we performed ATAC-seq analysis of a myoblast-based model of FP-RMS in which MST was further inhibited and found the RUNX2 gene locus was more accessible. Since RUNX2 is a pioneer transcription factor known to interact with the "WW" domains of Hippo pathway members to support mesenchymal cell fate, we hypothesize that RUNX2 maintains these relationships to support FP-RMS cell state and survival. Methods & Results: Inquiry of in silico databases and previously published literature unveiled that sarcomas including RMS have a high dependency on RUNX2 and that P3F directly binds a RUNX2 enhancer. Interrogation of a proximity labeling proteomics study from our collaborators in the Counter lab found that RUNX2 was part of the protein interactome of 7/7 FP-RMS fusions including P3F. Additionally, Co-IP experiments confirmed that there is a direct protein-protein relationship between RUNX2, P3F, and TAZ. Next, we performed in vitro genetic loss of function (LOF) of RUNX2 using RNAi, which showed that suppression of RUNX2 caused cell death, growth inhibition, increased TAZ expression, and induction of both myogenic and osteogenic markers. We also performed complementary pharmacologic LOF using two available small molecules, AI-14-91 (Bushweller lab) in vitro, and CADD522 (commercially available) in vitro and in vivo. We found that these partially phenocopied the genetic LOF and that CADD522 reduces tumor volume and growth. Conclusions: RUNX2 is a vulnerability in RMS based on in silico, in vitro, and in vivo investigation, and may act to prevent osteogenic and myogenic differentiation via protein-protein relationships in the Hippo pathway. The next step will be assessing mechanistic relationships between the Hippo pathway and RUNX2, as well as the genome wide changes upon RUNX2 LOF by performing ChIP-seq, RNA-seq, and scRNA-seq experiments. Citation Format: Elizabeth A. Mendes, Audrey L. Chambers, Samantha J. Weitzel, Michael Deel, Aanandi Munshi, Christopher M. Counter, Seth Zimmerman, John Bushweller, Corinne M. Linardic. RUNX2 inhibition alters PAX3::FOXO1 driven fusion-positive rhabdomyosarcoma cell state and growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1092.

oncology
Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism

Ritesh K. Srivastava,Purushotham Guroji,Lin Jin,M. Shahid Mukhtar,Mohammad Athar

DOI: https://doi.org/10.1002/mc.23414

2022-04-26

Molecular Carcinogenesis

Abstract:Aberrant activation of multiple complex signaling pathways underlies the pathogenesis of rhabdomyosarcoma (RMS), which remains a cause of mortality in approximately 30% of children with RMS. Bromodomain and extraterminal (BET) domain chromatin remodeling regulates several of these pathways. Here, we targeted bromodomain 4 (BRD4) in combination with another molecular metabolic tumor driver, the Akt/mTOR signaling pathway, to provide a highly effective treatment for this neoplasm. We demonstrated that a nexus of these two molecular pathways underlies RMS pathogenesis. Our data show that the combined inhibition of the BET bromodomain and mTORC1/2 signaling abrogates aggressive RMS growth. Thus, the bromodomain inhibitor RVX‐208 significantly augmented the therapeutic effects of the dual mTORC1/2 inhibitors, OSI‐027 and PP242, both in vitro and in a human xenograft murine model. Drug‐treated residual tumors showed a decrease in the activation of underlying signaling mechanisms characterized by a reduction in the expression of p‐AKT, p‐mTOR, p‐p70S6K, cyclin D1, and proliferation. Our ChIP‐seq data demonstrated that RVX‐208 effectively blocked BRD4 occupancy on its target promoters. ChIP‐qPCR assays further confirmed that RVX‐208 treatment resulted in a significant decrease in H3K27ac and H4K8ac signals at their target loci. While single RVX‐208 treatment induces apoptosis and a single mTORC1/2 inhibitor induces macropinocytosis, their combined treatment led to necroptosis‐mediated cell death. These data suggest that combined treatment with drugs targeting BRD4 and mTORC1/2 may be an effective therapeutic intervention for drug‐resistant RMS.

oncology,biochemistry & molecular biology
Anlotinib, a Novel Small Molecular Tyrosine Kinase Inhibitor, Suppresses Growth and Metastasis Via Dual Blockade of VEGFR2 and MET in Osteosarcoma

Gangyang Wang,Mengxiong Sun,Yafei Jiang,Tao Zhang,Wei Sun,Hongsheng Wang,Fei Yin,Zhuoying Wang,Weilin Sang,Jing Xu,Min Mao,Dongqing Zuo,Zifei Zhou,Chongren Wang,Zeze Fu,Zongyi Wang,Zhenfeng Duan,Yingqi Hua,Zhengdong Cai

DOI: https://doi.org/10.1002/ijc.32180

2019-01-01

International Journal of Cancer

Abstract:Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with highly aggressive behavior and early systemic metastasis. The survival rates for osteosarcoma remain unchanged over the past two decades. Studies aiming to find new or alternative therapies for patients with refractory osteosarcoma are urgently needed. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor (TKI), has exhibited encouraging clinical activity in NSLCC and soft tissue sarcoma, whereas its effect on osteosarcoma has not been studied. In our study, we investigated the anti-tumor activity and underlying mechanism of anlotinib in osteosarcoma. Various in vitro and in vivo models of human osteosarcoma were used to determine the anti-proliferative, anti-angiogenesis and anti-metastasis efficacy of anlotinib. Our results showed that anlotinib suppressed tumor growth and increased the chemo-sensitivity of osteosarcoma. In addition, anlotinib inhibited migration and invasion in osteosarcoma cells. Furthermore, in order to explore the anti-tumor mechanism of anlotinib, phospho-RTK antibody arrays were performed. These analyses confirmed that anlotinib suppressed the phosphorylation of MET, VEGFR2 and the downstream signaling pathway activation. Moreover, we demonstrated that anlotinib blocked hepatocyte growth factor (HGF)-induced cell migration, invasion and VEGF-induced angiogenesis. Notably, a 143B-Luc orthotopic osteosarcoma model further showed that anlotinib significantly inhibited growth and lung metastasis of implanted tumor cells. Our preclinical work indicates that anlotinib acts as a novel inhibitor of VEGFR2 and MET that blocks tumorigenesis in osteosarcoma, which could be translated into future clinical trials.
Phase I study of anlotinib in pediatric patients with high-risk, recurrent, or refractory sarcomas.

Suying Lu,Juan Wang,Feifei Sun,Junting Huang,Jia Zhu,Ruiqing Cai,Zijun Zhen,Yizhuo Zhang

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e23538

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e23538 Background: Anlotinib is an orally available, highly potent, novel multitargeted tyrosine kinase inhibitor, which blocks VEGF signaling by selectively targeting VEGFR-2, -3 as well as FGFR-1, -2, -3, -4 with high affinity. We evaluated the toxicity, and pharmacokinetic profile of anlotinib in children with high-risk, recurrent, or refractory sarcomas. Methods: This was an open-label, single-center, single-arm phase I study, which enrolled pediatric patients with sarcoma. Pediatric patients aged 5-18 years diagnosed with high-risk, recurrent, or refractory sarcomas were enrolled and further categorized into cohort A (<35 kg) or cohort B (≥ 35kg). Anlotinib was administered orally, once daily, 2-week on off, until disease progression, death, unacceptable toxicity, or withdrawal of consent for any reasons. A fixed anlotinib level of 8 mg was given to cohort A and three dose levels (8mg, 10mg, 12mg) were evaluated using a “3 + 3” design in cohort B. Results: Between December 29, 2020, and September 7, 2022, 34 patients were enrolled to evaluate the safety and 19 (55.9%) were evaluable for efficacy. The median age was 12 (range 5-18) years old. The main subtype eligible was rhabdomyosarcoma (23.5%). Two of fifteen patients in cohort A at a dose level of 8 mg experienced dose-limiting toxicity, including grade 3 hematuria and grade 3 hand-foot syndrome. The grade 3 treatment-related adverse events (AEs) included neutropenia (3 [8.8%]), hand-foot syndrome (2 [5.9%]), headache (1 [2.9%]), hematuria (1 [2.9%]), hypertension (1 [2.9%]), and hyperbilirubinemia (1 [2.9%]). The most common AEs were grade 1 or 2 hypothyroidism (58.8%) and abdominal pain (55.9%). Twelve of 19 (63.2%) patients had a best response of stable disease with seven patients receiving ≥ 6 cycles. Age has no significant effect on the level of body exposure per unit body surface area dose, and patients younger than 12 years old had a faster elimination. Conclusions: Anlotinib in pediatric patients with sarcoma was well tolerated. The RP2D of anlotinib for future studies is 8 mg for patients< 35 kg and 12 mg for patients with ≥ 35kg. Clinical trial information: NCT04659733 . [Table: see text]

oncology
Current propagation between a plasma opening switch and a load during opening

G. Dolgachev,Y. Kalinin,A. Kingsep,A. Ushakov,R. Commisso,P. Ottinger,S. Swanekamp,B. Weber

DOI: https://doi.org/10.1109/PPPS.2001.1001825

2001-06-17

Abstract:During the initial stages of opening in a long-conduction-time (/spl sim/ps) plasma opening switch (POS), a current propagation phenomenon is observed between the POS and the load. In this paper, we review the experimental characterization of this current propagation phenomenon and summarize the models proposed to describe it. Our goal is to consider the physical scenario of POS operation, regardless to particular POS construction and parameters. At present moment, electron magnetohydrodynamics (EMHD) seems to be a good basis to describe the POS conduction phase which probably determines all the basic output characteristics of POS. Sometimes, however, the anomalous resistivity joins the game.
Abstract 706: Advancing radiotherapy strategies for high-risk rhabdomyosarcoma: Unveiling BCL-xL inhibition as a potent sensitizer to radiotherapy

Sammy Se Whee Park,Nona Struyf,Tom Erkers,Sören Lehmann,Michael T. Meister,Jarno Drost,Frank C. Holstege,Nikolas Herold,Päivi Östling,Jakob Stenman,Olli Kallioniemi,Jan-Inge Henter,Brinton Seashore-Ludlow,Kasper Karlsson

DOI: https://doi.org/10.1158/1538-7445.am2024-706

IF: 11.2

2024-03-24

Cancer Research

Abstract:Pediatric soft-tissue sarcomas are a group of solid tumors that account for about 7% of childhood cancer cases. Rhabdomyosarcoma (RMS), the most common subtype, further stratifies into PAX3 or PAX7 and FOXO1 fusion-negative (FN) or fusion-positive (FP) RMS. FP RMS is the higher risk subtype and is more aggressive, metastatic, and less responsive to treatment. Front-line treatments for RMS FP patients have had limited progress in the recent years and existing treatments such as radiotherapy lacks tumor cell selectivity, resulting in toxic side effects. To address this, we conducted a high-throughput drug screen to identify radiosensitizers to enhance efficacy of RMS radiotherapy. Using three patient-derived FP RMS tumoroids, we screened a comprehensive drug library with and without radiation, comprising 528 drugs at varying stages of pre-clinical and clinical trials. A validation screen of the top 29 drugs was conducted on a larger cohort of samples including eight patient-derived FP RMS tumoroids and three non-cancer models. The screening revealed that drugs targeting the anti-apoptotic protein B-cell lymphoma-extra-large (BCL-xL) exhibited both potent radiosensitization and cytotoxicity selectively for FP RMS. Notably, the sensitivity to BCL-xL inhibitors correlated with elevated BCL2L1 expression and PAX3 fusion status. Additionally, drugs targeting polo-like kinase 1 (PLK1) and other cell cycle-related genes exhibited robust radioprotective effects across both RMS and non-cancer models. Our findings propose the therapeutic potential of BCL-xL inhibition, either as a standalone treatment or in combination with radiotherapy. In parallel, we show the protective potential of PLK1 inhibition to mitigate radiation toxicity. In the long term, we aspire to integrate the identified radiosensitizing and radioprotecting compounds with existing treatment regiments for RMS, maximizing precision and efficacy in RMS radiotherapy. Citation Format: Sammy Se Whee Park, Nona Struyf, Tom Erkers, Sören Lehmann, Michael T. Meister, Jarno Drost, Frank C. Holstege, Nikolas Herold, Päivi Östling, Jakob Stenman, Olli Kallioniemi, Jan-Inge Henter, Brinton Seashore-Ludlow, Kasper Karlsson. Advancing radiotherapy strategies for high-risk rhabdomyosarcoma: Unveiling BCL-xL inhibition as a potent sensitizer to radiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 706.

oncology
Abstract 143: Molecular profiling of tumor-initiation events in rhabdomyosarcoma uncovers mitochondrial vulnerabilities

Bhargab Kalita,Gerard Martinez-Cebrian,Justina McEvoy,Brittney Gordon,Kaley Blankenship,Asa Karlstorm,Elizabeth Stewart,Michael Dyer,Brian Dynlacht

DOI: https://doi.org/10.1158/1538-7445.am2024-143

IF: 11.2

2024-03-24

Cancer Research

Abstract:Background: Alveolar Rhabdomyosarcoma (ARMS) is a very aggressive soft tissue tumor affecting children and adolescents. It is found that pediatric patients with RMS harboring chimeric PAX fusion transcription factors (TFs) exhibit a greater incidence of tumor relapse, metastasis, and poor survival outcome, thereby underscoring the urgent need to develop effective therapies to treat this subtype of childhood cancer. Methods: We generated a novel ARMS model by stable transduction of myogenic progenitor cells with a cassette encoding the exact PAX3/7-FOXO1 fusion protein found in ARMS tumors. We analyzed genome-wide expression levels with RNA-seq and utilized Cut&Run to map the binding sites of PAX3/7-FOXO1, active histone marks, enhancers, and super-enhancers in our novel model. Hi-C and promoter capture HiC (pCHiC) were also performed to generate 3D chromatin conformation maps in cells expressing the oncogenic TFs. We compared these data with analogous datasets from orthotopic patient-derived xenografts (O-PDXs) of PAX3/7-FOXO1 fusion-positive ARMS tumors from St. Jude and established ARMS cell lines to validate whether our model system recapitulates ARMS tumors. CRISPRi was performed to silence key targets in two representative ARMS cell lines and proliferation was scored after silencing. Next, we found that ARMS tumors displayed anomalies in mitochondrial mass and numbers, metabolic parameters, and membrane potential by performing TEM, Seahorse assays, and FACS-based TMRM and mitotracker Red dye uptake in a panel of ARMS cells and PDX samples. We performed cell viability and colony forming assays in ARMS cells treated with single drugs and combinations of drugs targeting FGFR4 and mitochondrial metabolism. Results: Our data provide evidence to support muscle progenitors as potential cells-of-origin for ARMS. We showed that rewiring of chromatin architecture mediated by PAX3/7-FOXO1 TFs is evident across established cell lines, primary tumors as well as O-PDXs. By integrating PAX3/7-FOXO1 binding, RNA-seq, and pCHiC data, we identified key promoter-enhancer (P-En) interactions that are erased or established de novo at multiple loci of master TFs like MYOD, MYOG and MYCN. We also identified key regulators of proliferation, including FGFR4, and mitochondrial function that are essential for tumor growth and invasiveness. Our data indicated aberrant and enhanced mitochondrial metabolism in ARMS as well as selective sensitivity to mitochondrial inhibitors in RMS cells. Administration of these inhibitors preferentially inhibited cell viability and clonogenicity in ARMS, and prompted a pre-clinical phase II study to test these inhibitors at St. Jude Research Hospital. Conclusion: We present a novel treatment strategy leveraging the mitochondrial dependencies of fusion positive PAX-driven tumors which can be exploited for precision therapy in high-risk ARMS. Citation Format: Bhargab Kalita, Gerard Martinez-Cebrian, Justina McEvoy, Brittney Gordon, Kaley Blankenship, Asa Karlstorm, Elizabeth Stewart, Michael Dyer, Brian Dynlacht. Molecular profiling of tumor-initiation events in rhabdomyosarcoma uncovers mitochondrial vulnerabilities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 143.

oncology
NFκB signaling in alveolar rhabdomyosarcoma

Megan M. Cleary,Atiya Mansoor,Teagan Settelmeyer,Yuichi Ijiri,Katherine J. Ladner,Matthew N. Svalina,Brian P. Rubin,Denis C. Guttridge,Charles Keller,Megan M. Cleary,Atiya Mansoor,Teagan Settelmeyer,Yuichi Ijiri,Katherine J. Ladner,Matthew N. Svalina,Brian P. Rubin,Denis C. Guttridge,Charles Keller

DOI: https://doi.org/10.1242/dmm.030882

2017-09-01

Abstract:ABSTRACT Alveolar rhabdomyosarcoma (aRMS) is a pediatric soft tissue cancer commonly associated with a chromosomal translocation that leads to the expression of a Pax3:Foxo1 or Pax7:Foxo1 fusion protein, the developmental underpinnings of which may give clues to its therapeutic approaches. In aRMS, the NFκB–YY1–miR-29 regulatory circuit is dysregulated, resulting in repression of miR-29 and loss of the associated tumor suppressor activity. To further elucidate the role of NFκB in aRMS, we first tested 55 unique sarcoma cell lines and primary cell cultures in a large-scale chemical screen targeting diverse molecular pathways. We found that pharmacological inhibition of NFκB activity resulted in decreased cell proliferation of many of the aRMS tumor cultures. Surprisingly, mice that were orthotopically allografted with aRMS tumor cells exhibited no difference in tumor growth when administered an NFκB inhibitor, compared to control. Furthermore, inhibition of NFκB by genetically ablating its activating kinase inhibitor, IKKβ, by conditional deletion in a mouse model harboring the Pax3:Foxo1 chimeric oncogene failed to abrogate spontaneous tumor growth. Genetically engineered mice with conditionally deleted IKKβ exhibited a paradoxical decrease in tumor latency compared with those with active NFκB. However, using a synthetic-lethal approach, primary cell cultures derived from tumors with inactivated NFκB showed sensitivity to the BCL-2 inhibitor navitoclax. When used in combination with an NFκB inhibitor, navitoclax was synergistic in decreasing the growth of both human and IKKβ wild-type mouse aRMS cells, indicating that inactivation of NFκB alone may not be sufficient for reducing tumor growth, but, when combined with another targeted therapeutic, may be clinically beneficial.

pathology,cell biology
Entinostat as a combinatorial therapeutic for rhabdomyosarcoma

Shefali Chauhan,Emily Lian,Iman Habib,Qianqian Liu,Nicole M. Anders,Megan M. Bugg,Noah C. Federman,Joel M. Reid,Clinton F. Stewart,Tristan Cates,Joel E. Michalek,Charles Keller

DOI: https://doi.org/10.1038/s41598-024-66545-5

IF: 4.6

2024-08-18

Scientific Reports

Abstract:Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. For the alveolar subtype (ARMS), the presence of the PAX3::FOXO1 fusion gene and/or metastases are strong predictors of poor outcome. Metastatic PAX3::FOXO1 + ARMS often responds to chemotherapies initially, only to subsequently relapse and become resistant with most patients failing to survive beyond 8 years post-diagnosis. No curative intent phase II or phase III clinical trial has been available for patients in the past 10 years (ARST0921). Thus, metastatic ARMS represents a significantly unmet clinical need. Chemotherapy resistance in ARMS has previously been attributed to PAX3::FOXO1-mediated cell cycle checkpoint adaptation, which is mediated by an HDAC3-SMARCA4- miR-27a -PAX3::FOXO1 circuit that can be disrupted by HDAC3 inhibition. In this study, we investigated the therapeutic efficacy of combining the epigenetic regulator entinostat, a Class I Histone Deacetylase (HDAC1-3) inhibitor, with RMS-specific chemotherapies in patient derived xenograft (PDX) models of RMS. We identified single agent, additive or synergistic relationships between relapse-specific chemotherapies and clinically relevant drug exposures of entinostat in three PAX3::FOXO1 + ARMS mouse models. This preclinical data provides further rationale for clinical investigation of entinostat, already known to be well tolerated in a pediatric phase I clinical trial (ADVL1513).

multidisciplinary sciences
BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Qingtao Meng,Jian Han,Peng Wang,Chenxu Jia,Mingyang Guan,Bolun Zhang,Wenzhi Zhao

DOI: https://doi.org/10.1016/j.jbo.2024.100594

IF: 4.491

2024-03-17

Journal of Bone Oncology

Abstract:Background Osteosarcoma, a tumor that originates from bone cells, has a poor prognosis and a high degree of malignancy. Anlotinib, a small-molecule multi-target tyrosine kinase inhibitor (TKI), is the first-line drug in treating osteosarcoma, especially in late-stage osteosarcoma. However, patients often develop resistance after using anlotinib for a certain period, which poses a challenge to its further clinical application. Recently, several TKIs, for instance regorafenib and cabozantinib, have showed clinical interest in treating osteosarcoma and target both vascular endothelial growth factor receptor (VEGFR) and mesenchymal epithelial transition factor (c-MET). Therefore, the identification of new TKI warrants further investigation. Methods We performed CCK8 aasays to confirm that BMS-794833 sensitization osteosarcoma cells to anlotinib. Bioinformatics analysis and rescue experiments showed that the reduce of resistance were dependent on the VEGFR/Ras/CDK2 pathway. Cell line based xenograft model were used to demonstrate that BMS-794833 and anlotinib could synergistically treat OS. Results Here, we found that BMS-794833 reduced anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway. CCK8 assay showed that BMS-794833 significantly improved the resistance of osteosarcoma cells to anlotinib. The results of rescue experiments showed that the regulatory effects of BMS-794833 on the proliferation and drug resistance of osteosarcoma cells were dependent on the VEGFR/Ras/CDK2 pathway. In addition, BMS-794833 affected the resistance of osteosarcoma cells to anlotinib through epithelial–mesenchymal transition (EMT) and apoptosis pathways. More importantly, BMS-794833 and anlotinib exerted synergistic therapeutic effects against osteosarcoma in vivo . Conclusion Altogether, this study reveals a new (VEGFR)-targeting drug that can be combined with anlotinib for the treatment of osteosarcoma, which provides an important theoretical basis for overcoming anlotinib resistance.

oncology
Abstract 136: Determining the genomic basis of PAX3-FOXO1 mediated transformation in rhabdomyosarcoma

Bradley T. Stevens,Yang Zhang,Randolph K. Larsen,Grace E. Adkins,Jack D. Hopkins,Darden W. Kimbrough,Matthew R. Garcia,Brian J. Abraham,Mark E. Hatley

DOI: https://doi.org/10.1158/1538-7445.am2024-136

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite rigorous scientific advances and clinical trials, the survival rate for high-risk RMS has not increased above 20% in the last three decades. A deeper understanding of the basic biology driving RMS tumorigenesis is needed to discover novel therapeutic targets. RMS can be divided into two major histologic subtypes: embryonal RMS (ERMS) and alveolar RMS (ARMS). ARMS accounts for 20% of pediatric cases and has poorer survival. The majority of ARMS tumors harbor t(2;13)(q35;q14) or t(1;13)(p36;q14) chromosomal translocations resulting in the PAX3-FOXO1 (P3F) and PAX7-FOXO1 (P7F) fusion oncoproteins, respectively. ARMS tumors that lack oncofusions more closely resemble ERMS. Classifying on fusion status more accurately describes the disease and highlights the significance of P3/7F. ARMS tumor genomes only contain an average of 6.4 somatic mutations suggesting the oncofusion protein is the key oncogenic driver and a potential candidate for therapeutic intervention. RMS is commonly thought to arise from skeletal muscle progenitor cells that fail to terminally differentiate. However, RMS occurs throughout the body in sites devoid of skeletal muscle, underscoring the potential for alternative cells of origin. Our lab established that endothelial progenitors are indeed a cell of origin for ARMS by generating a genetically engineered mouse model with endothelial cell specific P3F expression coupled with Cdkn2a loss. We further generated a human model system derived from TP53-null human induced pluripotent stem cells (iPSCs), in which we direct differentiation to endothelial cell fate and then force P3F expression. P3F expression during endothelial cell directed differentiation blocked endothelial maturation and instead reprogrammed cells shifting cell fate to skeletal muscle-like cells that form ARMS tumors in mice. Generation of iPSC-derived ARMS (iARMS) occurs over 15 days and provides a unique model to determine the kinetics and specific genomic contributions facilitated by P3F during RMS transformation. To investigate the genomic changes occurring during iARMS transformation I utilized CUT&RUN for P3F and H3K27ac to assess P3F occupancy and enhancer landscape, ATAC-seq to assess chromatin accessibility, and RNA-seq to assess gene expression changes at timepoints throughout the transformation event. These results define the fundamental genomic changes needed for transformation into FP-RMS by P3F and uncovers the key determinants of ARMS cell identity. The iARMS system provides a unique platform to uncover how P3F establishes and maintains RMS cell state and to dissect the specific dependencies required to maintain the ARMS cell state. Understanding the fundamental mechanism of P3F-driven tumorigenesis could provide greater resolution into the key disease determinants to focus pre-clinical efforts on pivotal targets. Citation Format: Bradley T. Stevens, Yang Zhang, Randolph K. Larsen, Grace E. Adkins, Jack D. Hopkins, Darden W. Kimbrough, Matthew R. Garcia, Brian J. Abraham, Mark E. Hatley. Determining the genomic basis of PAX3-FOXO1 mediated transformation in rhabdomyosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 136.

oncology
Evaluation of the role of AXL in fusion-positive pediatric rhabdomyosarcoma identifies the small-molecule inhibitor bemcentinib (BGB324) as potent chemosensitizer

Sara G. Danielli,Jakob Wurth,Sarah Morice,Samanta Kisele,Didier Surdez,Olivier Delattre,Peter K. Bode,Marco Wachtel,Beat W. Schafer

DOI: https://doi.org/10.1158/1535-7163.mct-23-0285

2024-03-13

Molecular Cancer Therapeutics

Abstract:Abstract Rhabdomyosarcoma (RMS) is a highly aggressive pediatric cancer with features of skeletal muscle differentiation. Over 80% of the high-risk patients ultimately fail to respond to chemotherapy treatment, leading to limited therapeutic options and dismal prognostic rates. The lack of response - and subsequent tumor recurrence - is driven in part by stem cell-like cells, the tumor subpopulation that is enriched after treatment, and characterized by expression of the AXL receptor tyrosine kinase (AXL). AXL mediates survival, migration and therapy resistance in several cancer types; however, its function in RMS remains unclear. In this study, we investigated the role of AXL in RMS tumorigenesis, migration and chemotherapy response, and whether targeting of AXL with small molecule inhibitors could potentiate the efficacy of chemotherapy. We show that AXL is expressed in a heterogeneous manner in patient-derived xenografts (PDXs), primary cultures and cell line models of RMS, consistent with its stem-cell-state selectivity. By generating a CRISPR/Cas9 AXL knock-out and overexpressing models, we show that AXL contributes to the migratory phenotype of RMS, but not to chemotherapy resistance. Instead, pharmacological blockade with the AXL inhibitors bemcentinib (BGB324), cabozantinib and NPS-1034 rapidly killed RMS cells in an AXL-independent manner, and augmented the efficacy of the chemotherapeutics vincristine and cyclophosphamide. In vivo administration of the combination of bemcentinib and vincristine exerted strong anti-tumoral activity in a rapidly progressing PDX mouse model, significantly reducing tumor bruden compared to single-agent treatment. Collectively, our data identify bemcentinib as a promising drug to improve chemotherapy efficacy in RMS patients.

oncology
Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway

Qiuling Chen,Qian Lai,Yuelong Jiang,jingwei Yao,Qinwei Chen,Li Zhang,Caiyan Wang,Yong Zhou,Manman Deng,Bing Xu

DOI: https://doi.org/10.1016/j.tranon.2022.101516

IF: 4.803

2022-11-01

Translational Oncology

Abstract:ObjectivesDespite advances in the development of novel targeted therapies, the need for B-ALL alternative treatments has not been met. Anlotinib could blunt the proangiogenic activity of VEGFR, PDGFR, and FGFR, and has shown strong antitumor activities across multiple tumors. However, anlotinib cytotoxicity against B-ALL has not ever been evaluated, thus prompting us to initiate this study.MethodsExpression2Kinases program was used to identify potential treatment targets. Cell viability and apoptosis were determined by CCK-8 and Annexin V/PI staining kit, respectively. qRT-PCR and Western blotting were utilized to investigate the molecular mechanisms. In vivo antileukemia activity of Anlotinib was evaluated in a Ph+ B-ALL patient-Derived Xenograft (PDX) model.ResultsCompared with treatment-naive B-ALL cases, RR B-ALL patients had higher activities in the VEGF/VEGFR signaling and the PI3K/AKT/mTOR pathway. Exposure of Ph− and Ph+ B-ALL cells to anlotinib resulted in significant cell viability reduction, apoptosis enhancement, and cell cycle arrest at G2/M phase. Importantly, anlotinib treatment led to remarkably decreased leukemia burdens and extended the survival period in a Ph+ B-ALL PDX model. Blockade of the role of the proangiogenic mediators, comprising VEGFR2, PDGFR-beta, and FGFR3, played a critical role in the cytotoxicity of anlotinib against Ph− and Ph+ B-ALL. Moreover, anlotinib dampened the activity of PI3K/AKT/mTOR pathway that resides in the convergence of the three mentioned proangiogenic signals.ConclusionThis work provides impressive preclinical evidence of anlotinib against Ph− and Ph+ B-ALL and raises a rationale for future clinical evaluation of this drug in the management of Ph− and Ph+ B-ALL.

oncology

Measurement of Elecsys NT-proBNP in serum, K2 EDTA and heparin plasma.

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Targeting KDM4 for treating PAX3-FOXO1–driven alveolar rhabdomyosarcoma

Abstract 4738: Overcoming therapy resistance in rhabdomyosarcoma by targeting the PI3K-MAPK pathway

Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma

Abstract 1093: Small molecule inhibitors of the PAX3::FOXO1 fusion protein in rhabdomyosarcoma

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

PAX fusion proteins deregulate gene networks controlling mitochondrial translation in pediatric rhabdomyosarcoma

Abstract 1092: RUNX2 inhibition alters PAX3::FOXO1 driven fusion-positive rhabdomyosarcoma cell state and growth

Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism

Anlotinib, a Novel Small Molecular Tyrosine Kinase Inhibitor, Suppresses Growth and Metastasis Via Dual Blockade of VEGFR2 and MET in Osteosarcoma

Phase I study of anlotinib in pediatric patients with high-risk, recurrent, or refractory sarcomas.

Current propagation between a plasma opening switch and a load during opening

Abstract 706: Advancing radiotherapy strategies for high-risk rhabdomyosarcoma: Unveiling BCL-xL inhibition as a potent sensitizer to radiotherapy

Abstract 143: Molecular profiling of tumor-initiation events in rhabdomyosarcoma uncovers mitochondrial vulnerabilities

NFκB signaling in alveolar rhabdomyosarcoma

Entinostat as a combinatorial therapeutic for rhabdomyosarcoma

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Abstract 136: Determining the genomic basis of PAX3-FOXO1 mediated transformation in rhabdomyosarcoma

Evaluation of the role of AXL in fusion-positive pediatric rhabdomyosarcoma identifies the small-molecule inhibitor bemcentinib (BGB324) as potent chemosensitizer

Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway